MNG626
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.541
- E2F_TARGETS+0.392
- FATTY_ACID_METABOLISM+0.386
- OXIDATIVE_PHOSPHORYLATION+0.355
- G2M_CHECKPOINT+0.347
- GLYCOLYSIS+0.311
- MTORC1_SIGNALING+0.307
- PEROXISOME+0.306
- XENOBIOTIC_METABOLISM+0.264
- BILE_ACID_METABOLISM+0.260
Top 10 suppressed
- UV_RESPONSE_DN-0.492
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.426
- ANGIOGENESIS-0.369
- PANCREAS_BETA_CELLS-0.287
- TGF_BETA_SIGNALING-0.270
- HEDGEHOG_SIGNALING-0.241
- PROTEIN_SECRETION-0.186
- MYOGENESIS-0.173
- WNT_BETA_CATENIN_SIGNALING-0.169
- ANDROGEN_RESPONSE-0.150
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG713 | — | — | 0.838 |
| 2 | TCGA-GM-A3XL-01A-11R-A22U-07 | — | E | 0.836 |
| 3 | SRR6013495 | — | cohortA1 | 0.794 |
| 4 | 652298ba-554a-4fad-9d8b-aceaee37f9f2 | — | — | 0.793 |
| 5 | TCGA-AO-A0J2-01A-11R-A034-07 | — | C | 0.785 |
| 6 | TCGA-66-2758-01A-02R-0851-07 | — | cohortSQ2 | 0.782 |
| 7 | 992ce1bc-46a2-4f57-ac7a-c6368c69c67c | — | — | 0.781 |
| 8 | C3N-01419 | — | cohortA1 | 0.778 |
| 9 | SRR1516081 | — | — | 0.778 |
| 10 | SRR6013558 | — | cohortA4 | 0.777 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.541 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.392 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.386 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.355 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.347 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.311 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.307 | Inavolisib | — uncovered |
| PEROXISOME | 0.306 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.264 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.260 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.240 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.228 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.228 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.209 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.185 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.179 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.176 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.170 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.135 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.132 | Remibrutinib | — uncovered |